AMPH

#2181
Amphastar Pharmaceuticals, Inc. - Common Stock
18.8 5 USD
+9666.84%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
18.85
18.85
년간 변동
0.18
29.52
일일 변동
+9666.84%
월간 변동
-12.85%
6달 변화
-31.30%
년간 변동율
-22.68%
이전 종가
0.1 9
Open
18.8 5
저가
18.8 5
High
18.8 5
양
93
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 831.15 M
  • Employee 1 976
  • Founded 1996
  • CEO N/A
  • Website www.amphastar.com
  • Headquarter California, United States
  • FIGI BBG000BW90S6
  • Industry 전문의약품 및 제네릭 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
13.19
주가매출액비율
1.79

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

뉴스